loading
Precedente Chiudi:
$1.04
Aprire:
$1.05
Volume 24 ore:
67,666
Relative Volume:
0.39
Capitalizzazione di mercato:
$73.50M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-1.5143
EPS:
-0.7
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
-8.26%
1M Prestazione:
-11.34%
6M Prestazione:
-66.08%
1 anno Prestazione:
-67.84%
Intervallo 1D:
Value
$1.01
$1.07
Intervallo di 1 settimana:
Value
$0.9877
$1.19
Portata 52W:
Value
$0.68
$4.10

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name
Nome
Ovid Therapeutics Inc
Name
Telefono
212-776-4381
Name
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Name
Dipendente
25
Name
Cinguettio
@OvidRx
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
OVID's Discussions on Twitter

Confronta OVID con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
OVID 1.06 73.50M 391.70K -52.34M -45.92M -0.70
VRTX 450.91 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.94 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.93 24.89B 3.30B -501.07M 1.03B 11.54

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-04-20 Downgrade Cantor Fitzgerald Buy → Neutral
2021-03-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-12-02 Downgrade Citigroup Buy → Neutral
2020-12-02 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-09-04 Iniziato RBC Capital Mkts Outperform
2018-04-20 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Ovid Therapeutics Inc Borsa (OVID) Ultime notizie

pulisher
01:44 AM

B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World

01:44 AM
pulisher
Nov 20, 2024

Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat

Nov 20, 2024
pulisher
Nov 18, 2024

Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR

Nov 18, 2024
pulisher
Nov 16, 2024

Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters

Nov 15, 2024
pulisher
Nov 14, 2024

Ovid Therapeutics Inc (OVID) Quarterly 10-Q Report - Quartz

Nov 14, 2024
pulisher
Nov 14, 2024

William Blair Analysts Increase Earnings Estimates for OVID - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Ovid Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 12, 2024

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 08, 2024

US Penny Stocks To Watch This November 2024 - Simply Wall St

Nov 08, 2024
pulisher
Oct 31, 2024

Ovid Therapeutics to Host Investor Event - GlobeNewswire

Oct 31, 2024
pulisher
Oct 29, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat

Oct 29, 2024
pulisher
Oct 18, 2024

Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace

Oct 18, 2024
pulisher
Oct 18, 2024

Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com

Oct 18, 2024
pulisher
Oct 18, 2024

Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com

Oct 18, 2024
pulisher
Oct 05, 2024

Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents 2024 - Legal Service India

Oct 05, 2024
pulisher
Oct 04, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 04, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India

Oct 01, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada

Sep 30, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance

Sep 30, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat

Sep 30, 2024
pulisher
Sep 27, 2024

Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com

Sep 27, 2024
pulisher
Sep 26, 2024

Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan

Sep 26, 2024
pulisher
Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024
pulisher
Sep 24, 2024

Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Oxford Biomedica Sees Robust Growth in 2024 - TipRanks

Sep 23, 2024
pulisher
Sep 21, 2024

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

After epilepsy setback, Ovid charges confidently ahead in CNS - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily

Sep 18, 2024

Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):